Unraveling MLL1-fusion Leukemia: Epigenetic Revelations from an iPS Cell Point Mutation

Human iPS cells (WT ASE9203 cells) were obtained from Applied Stem Cell (ASC), and CRISPR-Cas9-mediated gene editing was completed by ASC using their proprietary CRISPR-Cas9 protocol to introduce the MLL1 Win motif R3765A. Two clones (MT1 and MT2) homozygous for R3765A were identified and sequenced. Both WT and MT iPS cells were maintained in mTeSRTM1 medium with 1x Supplement media (Stem Cell Technologies, Catalog #85850) and supplemented with 10 μM Y27632 (Stemgent) only upon thawing and passaging. ChIP seq analysis was performed. Compare ChIP-seq data for H3K4me3 in CRISPR-edited mutant and wild type human IPSC cells